Welcome!

News Feed Item

Stammering Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Stammering Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280948/Stammering-Global-Clinical-Trials-Review-H2-2014.html

Stammering Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Stammering Global Clinical Trials Review, H2, 2014" provides data on the Stammering clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Stammering. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Stammering. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Stammering 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Central and South America 12
Clinical Trials by G7 Countries: Proportion of Stammering to Central Nervous System Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Stammering to Central Nervous System Clinical Trials 16
Clinical Trials by Phase 17
In Progress Trials by Phase 18
Clinical Trials by Trial Status 19
Clinical Trials by End Point Status 20
Unaccomplished Trials of Stammering 21
Subjects Recruited Over a Period of Time 22
Clinical Trials by Sponsor Type 23
Prominent Sponsors 24
Clinical Trial Profiles 25
Clinical Trial Overview of Top Companies 25
Endo International plc 25
Clinical Trial Overview of Endo International plc 25
Clinical Trial Overview of Top Institutes / Government 26
National Institute on Deafness and Other Communication Disorders 26
Clinical Trial Overview of National Institute on Deafness and Other Communication Disorders 26
National Institute of Neurological Disorders and Stroke 27
Clinical Trial Overview of National Institute of Neurological Disorders and Stroke 27
The University of Sydney 28
Clinical Trial Overview of The University of Sydney 28
Tbilisi State Medical University 29
Clinical Trial Overview of Tbilisi State Medical University 29
Universidade Federal de Minas Gerais 30
Clinical Trial Overview of Universidade Federal de Minas Gerais 30
Pharmacology Research Institute 31
Clinical Trial Overview of Pharmacology Research Institute 31
The Newcastle upon Tyne Hospitals NHS Foundation Trust 32
Clinical Trial Overview of The Newcastle upon Tyne Hospitals NHS Foundation Trust 32
Universitatsklinikum Munster 33
Clinical Trial Overview of Universitatsklinikum Munster 33
University of California, Irvine 34
Clinical Trial Overview of University of California, Irvine 34
Five Key Clinical Profiles 35
Appendix 50
Abbreviations 50
Definitions 50
Research Methodology 51
Secondary Research 51
About GlobalData 52
Contact Us 52
Disclaimer 52
Source 52

List of Tables

Stammering Therapeutics, Global, Clinical Trials by Region, 2014* 6
Stammering Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Stammering Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Stammering Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 9
Stammering Therapeutics Clinical Trials, Europe, Top Countries, 2014* 10
Stammering Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Stammering Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 12
Proportion of Stammering to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Stammering Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Stammering Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Stammering to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Stammering Therapeutics, Global, Clinical Trials by Phase, 2014* 17
Stammering Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 18
Stammering Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Stammering Therapeutics Clinical Trials, Global, by End Point Status, 2014* 20
Stammering Therapeutics, Global, Suspended Clinical Trials, 2014* 21
Stammering Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Stammering Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 23
Stammering Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 24
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by Endo International plc, 2014* 25
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute on Deafness and Other Communication Disorders, 2014* 26
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Neurological Disorders and Stroke, 2014* 27
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Sydney, 2014* 28
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by Tbilisi State Medical University, 2014* 29
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by Universidade Federal de Minas Gerais, 2014* 30
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by Pharmacology Research Institute, 2014* 31
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by The Newcastle upon Tyne Hospitals NHS Foundation Trust, 2014* 32
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by Universitatsklinikum Munster, 2014* 33
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Irvine, 2014* 34

List of Figures

Stammering Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Stammering Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Stammering Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Stammering Therapeutics Clinical Trials, Europe, Top Countries (%), 2014* 10
Stammering Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 11
Proportion of Stammering to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Stammering Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Stammering Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Stammering to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Stammering Therapeutics, Global, Clinical Trials by Phase (%), 2014* 17
Stammering Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 18
Stammering Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Stammering Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Stammering Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 23
GlobalData Methodology 51

To order this report: Stammering Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280948/Stammering-Global-Clinical-Trials-Review-H2-2014.html

_________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at 20th Cloud Expo, Ed Featherston, director/senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
SYS-CON Events announced today that DatacenterDynamics has been named “Media Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY. DatacenterDynamics is a brand of DCD Group, a global B2B media and publishing company that develops products to help senior professionals in the world's most ICT dependent organizations make risk-based infrastructure and capacity decisions.
"Matrix is an ambitious open standard and implementation that's set up to break down the fragmentation problems that exist in IP messaging and VoIP communication," explained John Woolf, Technical Evangelist at Matrix, in this SYS-CON.tv interview at @ThingsExpo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
As software becomes more and more complex, we, as software developers, have been splitting up our code into smaller and smaller components. This is also true for the environment in which we run our code: going from bare metal, to VMs to the modern-day Cloud Native world of containers, schedulers and micro services. While we have figured out how to run containerized applications in the cloud using schedulers, we've yet to come up with a good solution to bridge the gap between getting your contain...
Growth hacking is common for startups to make unheard-of progress in building their business. Career Hacks can help Geek Girls and those who support them (yes, that's you too, Dad!) to excel in this typically male-dominated world. Get ready to learn the facts: Is there a bias against women in the tech / developer communities? Why are women 50% of the workforce, but hold only 24% of the STEM or IT positions? Some beginnings of what to do about it! In her Day 2 Keynote at 17th Cloud Expo, Sandy Ca...
"We host and fully manage cloud data services, whether we store, the data, move the data, or run analytics on the data," stated Kamal Shannak, Senior Development Manager, Cloud Data Services, IBM, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Information technology (IT) advances are transforming the way we innovate in business, thereby disrupting the old guard and their predictable status-quo. It’s creating global market turbulence. Industries are converging, and new opportunities and threats are emerging, like never before. So, how are savvy chief information officers (CIOs) leading this transition? Back in 2015, the IBM Institute for Business Value conducted a market study that included the findings from over 1,800 CIO interviews ...
IoT is at the core or many Digital Transformation initiatives with the goal of re-inventing a company's business model. We all agree that collecting relevant IoT data will result in massive amounts of data needing to be stored. However, with the rapid development of IoT devices and ongoing business model transformation, we are not able to predict the volume and growth of IoT data. And with the lack of IoT history, traditional methods of IT and infrastructure planning based on the past do not app...
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Niagara Networks exhibited at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. Niagara Networks offers the highest port-density systems, and the most complete Next-Generation Network Visibility systems including Network Packet Brokers, Bypass Switches, and Network TAPs.
WebRTC services have already permeated corporate communications in the form of videoconferencing solutions. However, WebRTC has the potential of going beyond and catalyzing a new class of services providing more than calls with capabilities such as mass-scale real-time media broadcasting, enriched and augmented video, person-to-machine and machine-to-machine communications. In his session at @ThingsExpo, Luis Lopez, CEO of Kurento, introduced the technologies required for implementing these idea...
Why do your mobile transformations need to happen today? Mobile is the strategy that enterprise transformation centers on to drive customer engagement. In his general session at @ThingsExpo, Roger Woods, Director, Mobile Product & Strategy – Adobe Marketing Cloud, covered key IoT and mobile trends that are forcing mobile transformation, key components of a solid mobile strategy and explored how brands are effectively driving mobile change throughout the enterprise.
Apache Hadoop is emerging as a distributed platform for handling large and fast incoming streams of data. Predictive maintenance, supply chain optimization, and Internet-of-Things analysis are examples where Hadoop provides the scalable storage, processing, and analytics platform to gain meaningful insights from granular data that is typically only valuable from a large-scale, aggregate view. One architecture useful for capturing and analyzing streaming data is the Lambda Architecture, represent...
SYS-CON Events announced today that delaPlex will exhibit at SYS-CON's @CloudExpo, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. delaPlex pioneered Software Development as a Service (SDaaS), which provides scalable resources to build, test, and deploy software. It’s a fast and more reliable way to develop a new product or expand your in-house team.
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...